AVLN — Avalyn Pharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1540171 ·
Last close
$32.29
Market Cap
$1.43B
52W High
$33.19
52W Low
$24.15
ADV30
328,684
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,909,000 | -26,869,000 | 135,663,000 | 92,310,000 | 399,908,000 |
| Mar 2025 | 0 | — | -18,716,000 | -17,503,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-49,166,000
Investing CF
$79,143,000
Financing CF
$14,862,000
CapEx
$-326,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.06
As of
2026-06-10
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -91,292,000 | -85,204,000 | 148,881,000 | 387,537,000 | — | -81,484,000 |
| Dec 2024 | 0 | -57,121,000 | -49,744,000 | 124,519,000 | 299,041,000 | — | -48,368,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KALV | KalVista Pharmaceuticals, Inc. | $1.44B | $27.00 | — |
| AKTS | Aktis Oncology, Inc. | $1.44B | $27.01 | — |
| DMRA | Damora Therapeutics, Inc. | $1.41B | $22.94 | — |
| ATAI | AtaiBeckley Inc. | $1.51B | $4.10 | — |
| ARDX | ARDELYX, INC. | $1.53B | $6.18 | — |
News headlines (Yahoo Finance, 1h cache)
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
2026-06-17 12:00 · Yahoo
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
2026-06-06 02:06 · Yahoo
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-06-03 11:00 · Yahoo
Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves
2026-06-01 20:08 · Yahoo
Avalyn to Participate in the Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
2026-05-21 12:00 · Yahoo
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
2026-05-05 20:01 · Yahoo
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-01 20:01 · Yahoo
Is Avalyn Pharma (NASDAQ:AVLN) In A Good Position To Invest In Growth?
2026-04-30 18:09 · Yahoo
Avalyn Announces Pricing of Upsized Initial Public Offering
2026-04-30 01:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.